NTU Singapore and Oxford study discover new process for cells to repair DNA damage
en-GBde-DEes-ESfr-FR

NTU Singapore and Oxford study discover new process for cells to repair DNA damage


A team of international researchers at the University of Oxford (Oxford) and Nanyang Technological University, Singapore (NTU Singapore), has discovered a new process for repairing damaged DNA that is particularly relevant for patients undergoing colorectal cancer treatments.

Reporting their finding in Cell, the researchers describe a new process in DNA repair in which cells remove harmful DNA-protein lesions from a cell’s nucleus, ensuring the stability of their genetic material and promoting cell survival. The team calls this new process nucleophagy.

Nucleophagy is a natural cellular cleaning mechanism known as autophagy that is essential for repairing DNA and ensuring cell survival. It involves a commonly expressed protein called TEX264.

In a patient receiving chemotherapy for colorectal cancer, the drugs cause DNA lesions to form. In response, the body expresses TEX264, which activates the nucleophagy process, guiding the lesions to the cell’s waste disposal system, where they are broken down and destroyed.

The research team used advanced techniques, including biochemical, cell biological and bioinformatics tools, zebrafish animal model and colorectal cancer patient materials, to confirm that nucleophagy is crucial for repairing damaged DNA.

This study provides insights into a new pathway for cells to repair DNA damage, which could improve cancer treatments and lead to better outcomes for patients in future, says the research team, which comprises scientists and clinicians.

Lead investigator Kristijan Ramadan, the Toh Kian Chui Distinguished Professor in Cancer and Stem Cell Biology, and Director of Cancer Discovery and Regenerative Medicine Programme at Lee Kong Chian School of Medicine (LKCMedicine), NTU Singapore, said, “While autophagy is known to be associated with DNA repair, there has been no evidence of its direct role in the repair of DNA lesions until now.”

“Our discovery that nucleophagy plays a direct role in DNA repair of chemotherapy-induced lesions is the result of a five-year joint effort among several laboratories in the UK, Singapore, USA, Portugal and Croatia,” added Prof Ramadan, who is also Medical Research Council Investigator at the Department of Oncology, Oxford.


Patients with high levels of TEX264 have better responses to cancer treatment

In particular, the research team says the findings are significant for patients with colorectal cancer – the second leading cause of cancer-related deaths worldwide, according to the World Health Organisation.

An analysis of colorectal cancer patients treated with Topoisomerase 1 inhibitors, such as FOLFIRI therapy (a common chemotherapy used to treat colorectal cancer), showed that patients with high levels of TEX264 in their tumours have a 50 per cent better response to treatment compared to those with low levels of TEX264.

First author of the study, Oxford’s Oncology DPhil student Pauline Lascaux, said, “This novel mechanism of DNA damage repair helps us comprehend how our cells maintain genetic integrity and respond to cancer treatments. This breakthrough opens avenues for a better understanding of how our body protects genetic material and how we can enhance the efficacy of cancer therapies for patients. I believe that modulating autophagy activity is the key to overcoming resistance to therapy in colorectal cancer.”

Commenting as an independent expert, Dr Jens Samol, Senior Consultant in Medical Oncology, Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, said, “Prof Ramadan and his international research team made a fascinating breakthrough discovery called nucleophagy, which could be a game-changer for more than just colorectal cancer patients. Some cancer treatments, like camptothecin and its variations, are already used to treat cancers like bowel, pancreas, ovarian, breast, and certain types of lung cancers. This new finding could help doctors better understand why some cancers resist treatment and pave the way for more effective therapies in the future.”

In future studies, the research team will explore the role of nucleophagy in the body’s response to chemotherapeutic drugs for other cancers, to see if their discovery is further validated. The team’s ultimate goal is to use this discovery to improve current chemotherapy responses for cancer patients.


Paper titled “TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival” published in Cell, 11 September 2024
https://doi.org/10.1016/j.cell.2024.08.020
Attached files
  • DNA (in blue) and the nuclear envelope (in green) found in the nuclei of cancer cells are attacked by the lysosomes (in red) after exposure to chemotherapy drugs as part of the nucleophagy-orchestrated DNA repair process.
  • The study was led by Kristijan Ramadan, the Toh Kian Chui Distinguished Professor in Cancer and Stem Cell Biology, and Director of Cancer Discovery and Regenerative Medicine Programme at Lee Kong Chian School of Medicine (LKCMedicine), NTU Singapore.
Regions: Asia, Singapore, Europe, Croatia, Portugal, United Kingdom, North America, United States
Keywords: Health, Medical, Well being, Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement